Psilocin vs. Psilocybin Effects in Healthy Adults

Overseen By Cesar Molina

Age: 18 - 65

Sex: Any

Trial Phase: Phase 1

Sponsor: University of California, San Francisco

Must not be taking: Dopamine agonists, MAO inhibitors

Disqualifiers: Other trial, Health condition, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 6

Duration: 8 hours per session

20 Participants Needed

Trial Summary

What is the purpose of this trial?

To compare the physiological and psychological effects of psilocin taken orally by pill or sublingually by dissolving a tablet under the tongue to those of psilocybin taken by pill in healthy adults.

Research Team

Joshua D Woolley, MD, PhD

Principal Investigator

University of California, San Francisco

Eligibility Criteria

This trial is for healthy adults aged 25-50 who are comfortable with English, have had a psychedelic experience before, and can commit to all study visits. They must not use THC, CBD, or nicotine during the study and should not be on certain medications like dopamine agonists or MAO inhibitors.

Inclusion Criteria

You have used psychedelic drugs before.

Commit to attending all study visits and remote data collection tasks

I do not have any surgeries planned during the study period.

Exclusion Criteria

Participated in another clinical trial within 30 days of entry to this trial

A health condition that makes study unsafe or unfeasible, determined by study physicians

I am not on medication that interacts badly with psilocybin.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Preparatory

Participants engage in preparatory visits with trained facilitators

1-2 weeks

Multiple visits (in-person)

Treatment

Participants receive psilocin or psilocybin in a randomized order, supervised by facilitators and a clinician

8 hours per session

Up to 4 sessions (in-person)

Integration

Participants complete assessment and integration sessions to process the experience

1-2 weeks

Multiple visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

2 visits (in-person)

Treatment Details

Interventions

• Psilocin
• Psilocybin
• Sublingual Psilocin

Trial Overview The trial aims to compare the effects of psilocin taken orally or sublingually with those of psilocybin in pill form. It will assess both physiological and psychological responses in participants.

Participant Groups

Group I: Oral & Sublingual Psilocin, & Oral Psilocybin Active Control 3 Interventions

Every participant will be administered Oral Psilocin, Sublingual Psilocin, and oral psilocybin in a randomized order.

Group II: Sublingual Psilocin Active Control 1 Intervention

Depending on a number of factors, participants may complete a fourth session where they receive sublingual psilocin for the second time.

Who Is Running the Clinical Trial?

University of California, San Francisco

Lead Sponsor

Trials

2,636

Recruited

19,080,000+

Filament Health Corp.

Industry Sponsor

Trials

4

Recruited

220+

Filament Health

Collaborator

Trials

2

Recruited

120+